Collection, access and use of human genetic information for precision medicines: Risk governance considerations

Gene technologies and their application by industry are developing rapidly, particularly in the US and in China. Yet, governance of the field of genomic for precision medicine is developing more slowly and needs to catch up. The rapid developments in science and technology but also in how cultures and values consider questions of ethics, privacy and data protection, pose challenges to regulators and policymakers. This report summarises some of the discussions at a workshop in August 2015.